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Two returning safari tourists with African trypanosomiasis were
admitted to the Hospital for Tropical Diseases, London, in a 3-
day period, compared with six cases in the previous 14 years.
We describe the clinical features, diagnosis, and problems
encountered in accessing appropriate therapy, and discuss the
potential for emergence of this disease in increasingly adven-
turous international travelers.
 51-year-old man returned from a 14-day game-viewing
vacation in the Luangwa Valley of southern Zambia on
October 11, 2000. He had been well while traveling but had
sustained numerous mosquito and tsetse fly bites. Two days
after his return, he noticed an enlarging, slightly tender,
erythematous lesion on his right shoulder (Figure 1a). Two
days later he became very ill with severe generalized myalgia,
abdominal discomfort, diarrhea, vomiting, headache, fever,
rigors, and sweats, but did not seek medical attention. On day
10 after his return, he consulted his primary-care physician and
was admitted to his local hospital. No malaria parasites were
seen on a blood film, but numerous trypomastigotes of Trypa-
nosoma sp. were identified, confirming the diagnosis of Afri-
can trypanosomiasis. The patient was transferred to the
Hospital for Tropical Diseases, London. The trypomastigotes
of  T. b. rhodesiense are indistinguishable morphologically
from those of T. b. gambiense, but from the epidemiology of
these infections the patient was presumed to have T. b. rhode-
siense infection, for which the recommended initial therapy is
intravenous suramin. 
Two days later the hospital admitted a second returning
traveler with  T. brucei (also presumed to be  rhodesiense)
infection, in this case acquired during a 14-day safari vacation
to Kenya and Tanzania. This 30-year-old male patient visited
the Ngorongoro Crater, Serengeti National Park, and Lake
Manyara (Figure 2), but noted tsetse bites only while in the
Serengeti, 7 days before symptom onset. He reported a 2-day
history of an enlarging, painless, nonpruritic skin lesion on his
neck, intermittent fever, a single rigor, and two brief episodes
of diarrhea and vomiting. A characteristic trypanosomal chan-
cre was present on the skin of the submandibular region (Fig-
ure 1b). The second patient also received intravenous suramin. 
Both patients exhibited a rapidly rising systemic inflamma-
tory response (initial C-reactive protein values 235 and 185
mg/L, respectively; normal <5 mg/L), lymphopenia (nadir
counts 0.1 and 0.42 x 109/L; normal range [NR] 1.5-4.0 x 109/
L), thrombocytopenia (nadir counts 30 and 119 x 109/L; NR
150-400 x 109/L), and mild hyponatremia (129 and 131 mmol/
L; NR 136-145 mmol/L). Neither patient had notable coagul-
opathy. Specific antitrypanosomal serologic testing by immun-
ofluorescence assay (IFA) yielded the following results:
patient 1: day 1 immunoglobulin (Ig) M 1:40, IgG negative;
day 28 IgM 1:20, IgG 1:80; and patient 2: day 1 IgM negative,
IgG 1:40; day 28 IgM 1:20, IgG 1:160. Screening dilution was
1:20. Specific antitrypanosomal IFA was negative for all cere-
brospinal fluid (CSF) samples tested.
Both patients were treated in accordance with a protocol
developed and used in Malawi and Uganda by workers from
the Liverpool School of Tropical Medicine. Intravenous
suramin (reconstituted in sterile water to a 10% solution, with
the required dose added to 200 mL 5% dextrose and infused
over 2 hours) is administered at doses of 5, 10, and 20 mg/kg
on days 1, 3, and 5, respectively (maximum 1.5 g/dose). Close
observation is needed to detect signs of an idiosyncratic
(anaphpylactic-type) reaction. Some authors recommend that a
test dose of 100 to 200 mg of suramin be given before the first
full dose, to exclude immediate hypersensitivity. Fresh CSF
samples are examined on day 5 to determine whether there is
evidence of central nervous system (CNS) involvement, as
defined by elevated IgM, pleocytosis, or presence of trypomas-
tigotes. Lumbar puncture is deliberately deferred until circulat-
ing trypanosomes have been cleared, to minimize the
theoretical risk of iatrogenic introduction of trypomastigotes
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Figure 1a. Trypanosomal
chancre on shoulder of
patient 1, with lymphangi-
tis toward axilla. 1b. Trypa-
nosomal chancre on throat
of patient 2.
a
bEmerging Infectious Diseases  •  Vol. 8, No. 1, January 2002 75
DISPATCHES
into the CSF. This delay also aids interpretation of CSF find-
ings as, even if there were blood in the CSF, any trypanosomes
found would still indicate CNS infection. CNS involvement is
treated with melarsoprol in 12 escalating doses over 4 weeks
and, although an accelerated 10-day schedule for T. b. gambi-
ense has recently undergone successful clinical trials in Angola
(1), this regimen has not been validated for the treatment of T.
b. rhodesiense. Suramin is ineffective in CNS disease; how-
ever, melarsoprol is a toxic arsenical compound associated in
some cases with encephalopathy, which can be fatal, and is
thus best avoided unless definitely required. If there is no evi-
dence of CNS involvement, therapy with suramin (20 mg/kg
intravenously, maximum 1.5 g/dose) is continued and adminis-
tered on days 9, 16, 23, and 30. 
Both our patients received the full 7 doses of suramin, as
neither had evidence of CNS disease on CSF examination.
Interestingly, both patients described a subjective dysesthesia
of the fingertips during suramin therapy, which resolved on
treatment completion and was not associated with any objec-
tive evidence of neuropathy on clinical examination. Transient
moderate proteinuria, a known side effect of suramin, was
noted in both patients and resolved after treatment.
The number of patients with imported T. b. rhodesiense
visiting clinicians in nonendemic areas is likely to increase.
For T. b. rhodesiense, which predominates in East Africa, wild
and domestic animals are important reservoirs. Wherever peo-
ple come into close proximity with these reservoirs (when vis-
iting game parks, for example) the potential exists for
transmission to humans by the tsetse fly vectors of the Gloss-
ina morsitans group. In contrast, for T. b. gambiense, which
predominates in West Africa, the human population itself is the
most important reservoir and G. palpalis tsetse flies are the
most important vector. The resurgence of sleeping sickness in
Africa is mainly due to T. b. gambiense. Countries reporting
epidemics of T. b. gambiense include Sudan, Angola, and the
Democratic Republic of Congo, where the number of cases
(certainly underreported) increased from 7,700 in 1990 to
27,044 in 1998 (2). The areas affected are not usually visited
by tourists or adventure travelers. Further epidemiologic infor-
mation is available on the World Health Organization website
(3). In large part, the resurgence of T. b. gambiense is due to
the breakdown of health systems in regions of civil and mili-
tary unrest and is cause for considerable concern.
Imported African trypanosomiasis has hitherto been rare in
the United Kingdom, with only six cases in the last 14 years at
the Hospital for Tropical Diseases, most recently in 1996.
Aside from the temporal proximity of the two cases described,
we were concerned that both patients had acquired infection in
areas commonly frequented by international safari-tourists
from around the world. We know of nine subsequent additional
European cases of imported African trypanosomiasis ( T. b.
rhodesiense) from Tanzania, and of an Australian who
acquired the infection from the same location in 1998 (4). In
1999 Sinha et al. reported only the 20th and 21st cases of T. b.
rhodesiense  infection imported into the United States (5).
However, increasing numbers of travelers are exposed to tsetse
fly bites in disease-endemic areas, and many of the game ani-
mals that the safari-tourist will view, including bushbuck,
waterbuck, and lion, are potential reservoirs. Furthermore, with
increases in tsetse fly activity reported in many regions of sub-
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Saharan Africa (including the Luangwa Valley), the potential
for further cases is substantial. Neither of the locations from
which our patients acquired their infections is novel, but the
sudden appearance of two cases in such a short time is note-
worthy. Clinicians should thus be alerted to the possibility of
an increase in cases of imported African trypanosomiasis in
safari-tourists. 
Next, we emphasize three key diagnostic points. First,
diagnosis in the two cases described was straightforward
because, as is often the case with early presentations of T. b.
rhodesiense, the patients had classic chancres and parasites
were easily identified in the blood. Had the patients delayed in
seeking medical attention or been exposed to T. b. gambiense,
identifying parasites in the blood would have been more diffi-
cult, leaving the risk of disease progression to neurologic
involvement before the diagnosis could be confirmed. Second,
when CSF samples are taken, either to confirm or exclude late-
stage neurologic trypanosomiasis, they must be examined in
the laboratory within 20 minutes of the sample’s being drawn.
After this time, the parasites are likely to lyse spontaneously
and be missed. Third, serology is not required for the diagnosis
of T. b. rhodesiense in blood, as the levels of parasitemia are
high. Furthermore, the number of T. b. rhodesiense clones cir-
culating in East Africa has led to problems with test sensitivity,
and the specificity is not well characterized. Serology, how-
ever, can aid the decision as to whether there is CNS involve-
ment.
Finally, we emphasize the difficulties that we encountered
(on a Saturday) in securing a supply of the therapeutic agent.
Suramin was available neither from our own pharmacy (the
last batch had been discarded after its expiration date passed 2
years earlier) nor from eight other regional tropical or infec-
tious disease units in the United Kingdom, France, and Bel-
gium. Previous use of suramin in oncology prompted us to
contact a large regional oncology unit in London, but the drug
was not available. Initial inquiries of hospital pharmacies in
Liverpool was not promising. However, a supply was finally
located at the Liverpool School of Tropical Medicine, and 3
doses, sufficient for 5 days of treatment, were sent to London
by courier. The rest of the drug, obtained from the Centers for
Disease Control and Prevention, arrived on day 5 after admis-
sion. The Hospital for Tropical Diseases has since secured a
supply of suramin from the manufacturer in Germany, which
we have in turn provided to another hospital for treatment of
another patient. 
There is grave concern about the international availability
of a number of antiparasitic drugs, with considerable uncer-
tainty about the sustainability of supplies of several, including
suramin and melarsoprol, which manufacturers deem commer-
cially unattractive. As the current epidemic of trypanosomiasis
continues, access to effective therapies must be ensured in dis-
ease-endemic areas. Although drug resistance is potentially a
serious problem, ensuring access to the currently available
therapies poses a considerable challenge, which ultimately
may depend on governmental or World Health Organization
intervention. This issue has also been highlighted recently
elsewhere (6).
A logistical problem in nonendemic areas, where imported
trypanosomiasis is likely to remain rare, is access to agents
such as suramin, for which the demand is small and which are
therefore very seldom stocked by general hospital pharmacies
but are needed urgently when a patient is admitted. Fortu-
nately, our first patient was relatively well and not adversely
affected by the 8-hour delay in initiation of therapy, but this
might not always be the case. It is vital that a mechanism is in
place to allow physicians working in nonendemic areas who
are involved in the management of patients from trypanosomi-
asis-endemic areas to have access to suramin and several other
essential but rarely used agents (such as melarsoprol, eflorni-
thine, nifurtimox, and benznidazole; the last two drugs used for
treatment of South American trypanosomiasis) from a central
repository 24 hours a day, 7 days a week.
Dr. Moore is specialist registrar in tropical medicine at the Hos-
pital for Tropical Diseases, London, and was previously an HIV
research fellow at the Kobler Center, Chelsea and Westminster Hospi-
tal, London.
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